C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Lymphoma, B-Cell|CAR-T
BIOLOGICAL: C752
The incidence and severity of adverse events (AEs), 1 year|Dose Limiting Toxicities, First 28 days s after C752 injection
Objective response rate (ORR), Objective response rate after C752 injection as defined by Lugano 2014, 1 year|PFS, 1 year|Pharmacokinetic - AUC, 1 year
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.